Beatriz MartÃ-nez-Delgado

List of Publications by Year
in descending order

65 papers	2,312 citations	249298 26 h-index	252626 46 g-index
68 all docs	68 docs citations	68 times ranked	4178 citing authors

#	Article	IF	Citations
1	De novo small deletion affecting transcription start site of short isoform of <scp>AUTS2</scp> gene in a patient with syndromic neurodevelopmental defects. American Journal of Medical Genetics, Part A, 2021, 185, 877-883.	0.7	5
2	A Novel Mouse Monoclonal Antibody C42 against C-Terminal Peptide of Alpha-1-Antitrypsin. International Journal of Molecular Sciences, 2021, 22, 2141.	1.8	0
3	Polymerization of misfolded Z alpha-1 antitrypsin protein lowers CX3CR1 expression in human PBMCs. ELife, 2021, 10, .	2.8	4
4	miR-320c Regulates SERPINA1 Expression and Is Induced in Patients With Pulmonary Disease. Archivos De Bronconeumologia, 2021, 57, 457-463.	0.4	10
5	Diagnostic Performance of a Lateral Flow Assay for the Detection of Alpha-1-Antitrypsin Deficiency. Archivos De Bronconeumologia, 2020, 56, 124-126.	0.4	6
6	Liver organoids reproduce alpha-1 antitrypsin deficiency-related liver disease. Hepatology International, 2020, 14, 127-137.	1.9	44
7	Frequency of low-level and high-level mosaicism in sporadic retinoblastoma: genotypeâ€“phenotype relationships. Journal of Human Genetics, 2020, 65, 165-174.	1.1	16
8	The Delivery of Î±1-Antitrypsin Therapy Through Transepidermal Route: Worthwhile to Explore. Frontiers in Pharmacology, 2020, 11, 983.	1.6	9
9	New cis-Acting Variants in PI*S Background Produce Null Phenotypes Causing Alpha-1 Antitrypsin Deficiency. American Journal of Respiratory Cell and Molecular Biology, 2020, 63, 444-451.	1.4	5
10	Five new cases of syndromic intellectual disability due to KAT6A mutations: widening the molecular and clinical spectrum. Orphanet Journal of Rare Diseases, 2020, 15, 44.	1.2	18
11	Clinical Significance of SERPINA1 Gene and Its Encoded Alpha1-antitrypsin Protein in NSCLC. Cancers, 2019, 11, 1306.	1.7	52
12	Characterization of Novel Missense Variants of SERPINA1 Gene Causing Alpha-1 Antitrypsin Deficiency. American Journal of Respiratory Cell and Molecular Biology, 2018, 58, 706-716.	1.4	24
13	Alpha-1 antitrypsin deficiency: outstanding questions and future directions. Orphanet Journal of Rare Diseases, 2018, 13, 114.	1.2	93
14	SpainUDP: The Spanish Undiagnosed Rare Diseases Program. International Journal of Environmental Research and Public Health, 2018, 15, 1746.	1.2	19
15	Registro espaÃ±ol de pacientes con dÃ©ficit de alfa-1 antitripsina: evaluaciÃ³n de la base de datos y anÃ¡lisis de la poblaciÃ³n incluida. Archivos De Bronconeumologia, 2017, 53, 13-18.	0.4	29
16	Identification of Novel Short C-Terminal Transcripts of Human SERPINA1 Gene. PLoS ONE, 2017, 12, e0170533.	1.1	13
17	Alpha-1 Antitrypsin Regulates Transcriptional Levels of Serine Proteases in Blood Mononuclear Cells. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 1065-1067.	2.5	4
18	Why do some adults with PiMZ Î±1-antitrypsin develop bronchiectasis?. ERJ Open Research, 2016, 2, 00021-2016.	1.1	5

#	Article	IF	Citations
19	MicroRNA deregulation in triple negative breast cancer reveals a role of miR-498 in regulating BRCA1 expression. Oncotarget, 2016, 7, 20068-20079.	0.8	42
20	MicroRNA expression signatures for the prediction of BRCA1/2 mutationâ€associated hereditary breast cancer in paraffinâ€embedded formalinâ€fixed breast tumors. International Journal of Cancer, 2015, 136, 593-602.	2.3	43
21	Alternative transcripts of the SERPINA1 gene in alpha-1 antitrypsin deficiency. Journal of Translational Medicine, 2015, 13, 211.	1.8	23
22	Tumor MicroRNA Expression Profiling Identifies Circulating MicroRNAs for Early Breast Cancer Detection. Clinical Chemistry, 2015, 61, 1098-1106.	1.5	183
23	miRNA expression profiling of formalin-fixed paraffin-embedded (FFPE) hereditary breast tumors. Genomics Data, 2015, 3, 75-79.	1.3	12
24	Severe alpha-1 antitrypsin deficiency in composite heterozygotes inheriting a new splicing mutation QOMadrid. Respiratory Research, 2014, 15, 125.	1.4	38
25	MicroRNA profile in very young women with breast cancer. BMC Cancer, 2014, 14, 529.	1.1	56
26	MicroRNA-based molecular classification of non-BRCA1/2 hereditary breast tumours. British Journal of Cancer, 2013, 109, 2724-2734.	2.9	23
27	Short telomeres are frequent in hereditary breast tumors and are associated with high tumor grade. Breast Cancer Research and Treatment, 2013, 141, 231-242.	1.1	23
28	DÃ©ficit de alfa-1-antitripsina asociado a la variante Matawa. Archivos De Bronconeumologia, 2013, 49, 548-550.	0.4	13
29	Shorter telomere length is associated with increased ovarian cancer risk in both familial and sporadic cases. Journal of Medical Genetics, 2012, 49, 341-344.	1.5	41
30	Mutational analysis of telomere genes in BRCA1/2-negative breast cancer families with very short telomeres. Breast Cancer Research and Treatment, 2012, 134, 1337-1343.	1.1	5
31	Deregulated miRNAs in Hereditary Breast Cancer Revealed a Role for miR-30c in Regulating KRAS Oncogene. PLoS ONE, 2012, 7, e38847.	1.1	71
32	Integration of BRCA1-mediated miRNA and mRNA profiles reveals microRNA regulation of TRAF2 and NFÎºB pathway. Breast Cancer Research and Treatment, 2012, 134, 41-51.	1.1	34
33	Abstract 5051: microRNA based classification of non-BRCA1/2 hereditary breast cancer tumors. , 2012, , .		0
34	Genetic Anticipation Is Associated with Telomere Shortening in Hereditary Breast Cancer. PLoS Genetics, 2011, 7, e1002182.	1.5	76
35	Abstract 1190: Integration of mRNA and miRNA signatures induced by BRCA1 gene. , 2011, , .		0
36	Molecular signature of response and potential pathways related to resistance to the HSP90 inhibitor, 17AAG, in breast cancer. BMC Medical Genomics, 2010, 3, 44.	0.7	25

#	Article	IF	Citations
37	The miR-200 family controls Â-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients. Endocrine-Related Cancer, 2010, 18, 85-95.	1.6	188
38	Evaluation of the BRCA1 interacting genes RAP80 and CCDC98 in familial breast cancer susceptibility. Breast Cancer Research and Treatment, 2009, 113, 371-376.	1.1	20
39	Current and future aggressive peripheral T-cell lymphoma treatment paradigms, biological features and therapeutic molecular targets. Critical Reviews in Oncology/Hematology, 2009, 71, 181-198.	2.0	20
40	Mitotic catastrophe cell death induced by heat shock protein 90 inhibitor in BRCA1-deficient breast cancer cell lines. Molecular Cancer Therapeutics, 2008, 7, 2358-2366.	1.9	25
41	Identification of a Proliferation Signature Related to Survival in Nodal Peripheral T-Cell Lymphomas. Journal of Clinical Oncology, 2007, 25, 3321-3329.	0.8	119
42	Expression of CYP3A4 as a predictor of response to chemotherapy in peripheral T-cell lymphomas. Blood, 2007, 110, 3345-3351.	0.6	42
43	Allelic expression and quantitative RT-PCR study of TAp73 and Î”Np73 in non-Hodgkin's lymphomas. Leukemia Research, 2006, 30, 170-177.	0.4	8
44	GrossSDHB deletions in patients with paraganglioma detected by multiplex PCR: A possible hot spot?. Genes Chromosomes and Cancer, 2006, 45, 213-219.	1.5	73
45	Peripheral T-cell lymphoma gene expression profiles. Hematological Oncology, 2006, 24, 113-119.	0.8	22
46	A haplotype containing thep53polymorphisms Ins16bp and Arg72Pro modifies cancer risk inBRCA2mutation carriers. Human Mutation, 2006, 27, 242-248.	1.1	35
47	Differential expression of NF-ÎºB pathway genes among peripheral T-cell lymphomas. Leukemia, 2005, 19, 2254-2263.	3.3	112
48	Identification of amplified and highly expressed genes in amplicons of the T-cell line huT78 detected by cDNA microarray CGH. Molecular Cancer, 2005, 4, 5.	7.9	4
49	Expression Profiling of T-Cell Lymphomas Differentiates Peripheral and Lymphoblastic Lymphomas and Defines Survival Related Genes. Clinical Cancer Research, 2004, 10, 4971-4982.	3.2	88
50	Gene expression analysis of chromosomal regions with gain or loss of genetic material detected by comparative genomic hybridization. Genes Chromosomes and Cancer, 2004, 41, 353-365.	1.5	17
51	Molecular study of a new family with hereditary renal cell carcinoma and a translocation t(3;8)(p13;q24.1). Human Genetics, 2003, 112, 178-185.	1.8	20
52	Characterization of the A673 cell line (Ewing tumor) by molecular cytogenetic techniques. Cancer Genetics and Cytogenetics, 2003, 141, 138-142.	1.0	57
53	Coincidental LOH regions in mouse and humans: evidence for novel tumor suppressor loci at 9q22?q34 in non-Hodgkin?s lymphomas. Leukemia Research, 2003, 27, 627-633.	0.4	18
54	Different Incidence and Pattern of p15INK4b and p16INK4a Promoter Region Hypermethylation in Hodgkin's and CD30-Positive Non-Hodgkin's Lymphomas. American Journal of Pathology, 2002, 161, 1007-1013.	1.9	58

#	Article	IF	Citations
55	Complex cytogenetic abnormalities including telomeric associations and MEN1 mutation in a pediatric ependymoma. Cancer Genetics and Cytogenetics, 2002, 138, 107-110.	1.0	14
56	Frequent inactivation of thep73gene by abnormal methylation or LOH in non-Hodgkin's lymphomas. International Journal of Cancer, 2002, 102, 15-19.	2.3	54
57	A rapid and easy method for multiple endocrine neoplasia type 1 mutation detection using conformation-sensitive gel electrophoresis. Journal of Human Genetics, 2002, 47, 190-195.	1.1	9
58	IgH, TCR-Î³, and TCR-Î² Gene Rearrangement in 80 B- and T-Cell Non-Hodgkin's Lymphomas: Study of the Association Between Proliferation and the So-called â€œAberrantâ€•Patterns. Diagnostic Molecular Pathology, 2001, 10, 69-77.	2.1	32
59	Chromosomal changes pattern and gene amplification in T cell non-Hodgkin's lymphomas. Leukemia, 2001, 15, 1627-1632.	3.3	31
60	Hypermethylation of P16ink4a and P15ink4b genes as a marker of disease in the follow-up of non-Hodgkin's lymphomas. British Journal of Haematology, 2000, 109, 97-103.	1.2	9
61	Identification by Comparative Genomic Hybridization of Genetic Changes Involved in Tumoral Progression of a T-Cell Non-Hodgkin Lymphoma. Cancer Genetics and Cytogenetics, 2000, 117, 41-44.	1.0	3
62	Genetic and clinical analysis in 10 Spanish patients with multiple endocrine neoplasia type 1. European Journal of Human Genetics, 1999, 7, 585-589.	1.4	14
63	CD19/CD5 acute lymphoblastic leukemia. , 1998, 31, 551-552.		12
64	Loss of p16/INK4A Protein Expression in Non-Hodgkin's Lymphomas Is a Frequent Finding Associated with Tumor Progression. American Journal of Pathology, 1998, 153, 887-897.	1.9	111
65	Correlation between mutations in p53 gene and protein expression in human lymphomas. , 1997, 55, 1-8.		32